Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pelvic Organ Prolapse | 2 | 2017 | 48 | 1.000 |
Why?
|
| Postoperative Complications | 4 | 2017 | 823 | 0.610 |
Why?
|
| Pyelonephritis, Xanthogranulomatous | 1 | 2018 | 2 | 0.560 |
Why?
|
| Nephrons | 1 | 2018 | 10 | 0.560 |
Why?
|
| Urinary Tract Infections | 3 | 2017 | 42 | 0.560 |
Why?
|
| Hemorrhage | 1 | 2018 | 95 | 0.530 |
Why?
|
| Reconstructive Surgical Procedures | 2 | 2017 | 191 | 0.520 |
Why?
|
| Disease Management | 1 | 2018 | 129 | 0.520 |
Why?
|
| Nephrectomy | 1 | 2018 | 123 | 0.510 |
Why?
|
| Postoperative Hemorrhage | 1 | 2017 | 38 | 0.510 |
Why?
|
| Vagina | 1 | 2017 | 61 | 0.500 |
Why?
|
| Surgical Mesh | 1 | 2017 | 50 | 0.490 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2017 | 47 | 0.490 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 99 | 0.480 |
Why?
|
| Pheochromocytoma | 1 | 2015 | 6 | 0.460 |
Why?
|
| Catecholamines | 1 | 2015 | 17 | 0.460 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2015 | 17 | 0.460 |
Why?
|
| Internship and Residency | 1 | 2017 | 319 | 0.410 |
Why?
|
| Urinary Tract | 1 | 2013 | 31 | 0.400 |
Why?
|
| Urologic Diseases | 1 | 2013 | 35 | 0.400 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2013 | 154 | 0.360 |
Why?
|
| Urinary Calculi | 1 | 2011 | 7 | 0.360 |
Why?
|
| Urine | 1 | 2011 | 69 | 0.340 |
Why?
|
| Ureter | 1 | 2011 | 39 | 0.340 |
Why?
|
| Hyperthermia, Induced | 1 | 2013 | 236 | 0.340 |
Why?
|
| Mineral Oil | 1 | 2010 | 4 | 0.330 |
Why?
|
| Sclerosis | 1 | 2010 | 9 | 0.330 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2010 | 7 | 0.330 |
Why?
|
| Peritoneal Neoplasms | 1 | 2013 | 256 | 0.320 |
Why?
|
| Middle Aged | 9 | 2018 | 11848 | 0.320 |
Why?
|
| Penis | 1 | 2010 | 45 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 443 | 0.320 |
Why?
|
| Kidney | 1 | 2011 | 521 | 0.260 |
Why?
|
| Neoplasms | 1 | 2013 | 754 | 0.250 |
Why?
|
| Databases, Factual | 2 | 2017 | 368 | 0.240 |
Why?
|
| Female | 9 | 2018 | 19942 | 0.230 |
Why?
|
| Humans | 14 | 2018 | 32274 | 0.230 |
Why?
|
| Retrospective Studies | 5 | 2017 | 3624 | 0.230 |
Why?
|
| Aged | 4 | 2017 | 10260 | 0.170 |
Why?
|
| Prognosis | 2 | 2015 | 1534 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 2240 | 0.150 |
Why?
|
| Adult | 6 | 2016 | 9256 | 0.150 |
Why?
|
| Male | 7 | 2017 | 19437 | 0.140 |
Why?
|
| Tuberculosis, Urogenital | 1 | 2017 | 2 | 0.130 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 6 | 0.130 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2017 | 10 | 0.130 |
Why?
|
| Cystocele | 1 | 2017 | 4 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2013 | 2316 | 0.130 |
Why?
|
| Hernia | 1 | 2017 | 11 | 0.130 |
Why?
|
| Pelvic Floor | 1 | 2017 | 23 | 0.130 |
Why?
|
| Uterine Prolapse | 1 | 2017 | 21 | 0.130 |
Why?
|
| Young Adult | 2 | 2015 | 2648 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 502 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2017 | 135 | 0.120 |
Why?
|
| Reoperation | 1 | 2017 | 252 | 0.120 |
Why?
|
| Nephrolithiasis | 1 | 2016 | 3 | 0.120 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2015 | 1 | 0.120 |
Why?
|
| Vertigo | 1 | 2015 | 3 | 0.120 |
Why?
|
| Dizziness | 1 | 2015 | 7 | 0.120 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 57 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2017 | 854 | 0.110 |
Why?
|
| Bioengineering | 1 | 2015 | 77 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 187 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3416 | 0.100 |
Why?
|
| Regenerative Medicine | 1 | 2015 | 217 | 0.100 |
Why?
|
| Kidney Calculi | 1 | 2012 | 23 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2015 | 863 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 461 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 555 | 0.090 |
Why?
|
| Specific Gravity | 1 | 2011 | 2 | 0.090 |
Why?
|
| Hardness | 1 | 2011 | 5 | 0.090 |
Why?
|
| Magnesium | 1 | 2011 | 29 | 0.090 |
Why?
|
| Sodium | 1 | 2011 | 41 | 0.090 |
Why?
|
| Potassium | 1 | 2011 | 40 | 0.090 |
Why?
|
| Nitrofurantoin | 1 | 2011 | 2 | 0.090 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2011 | 3 | 0.090 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 109 | 0.090 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 490 | 0.090 |
Why?
|
| Creatinine | 1 | 2011 | 191 | 0.090 |
Why?
|
| Survival Rate | 1 | 2013 | 893 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 534 | 0.090 |
Why?
|
| Laos | 1 | 2010 | 3 | 0.080 |
Why?
|
| Infusions, Subcutaneous | 1 | 2010 | 4 | 0.080 |
Why?
|
| Men's Health | 1 | 2010 | 10 | 0.080 |
Why?
|
| Plant Preparations | 1 | 2009 | 27 | 0.080 |
Why?
|
| Hypercholesterolemia | 1 | 2009 | 73 | 0.070 |
Why?
|
| Antioxidants | 1 | 2009 | 122 | 0.070 |
Why?
|
| Cholesterol | 1 | 2009 | 262 | 0.070 |
Why?
|
| Emigrants and Immigrants | 1 | 2010 | 198 | 0.070 |
Why?
|
| Urinary Bladder | 1 | 2010 | 320 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 907 | 0.060 |
Why?
|
| Tissue Engineering | 1 | 2010 | 695 | 0.050 |
Why?
|
| Adolescent | 1 | 2011 | 3517 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2009 | 820 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 1158 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 186 | 0.030 |
Why?
|
| Transplantation Immunology | 1 | 2015 | 30 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 556 | 0.030 |
Why?
|
| Risk Factors | 2 | 2016 | 3934 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2015 | 186 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2015 | 236 | 0.030 |
Why?
|
| Graft Survival | 1 | 2015 | 293 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 221 | 0.030 |
Why?
|
| Gases | 1 | 2012 | 3 | 0.020 |
Why?
|
| Calcium Phosphates | 1 | 2012 | 9 | 0.020 |
Why?
|
| Urinary Bladder Diseases | 1 | 2010 | 44 | 0.020 |
Why?
|
| Seeds | 1 | 2009 | 11 | 0.020 |
Why?
|
| Phytotherapy | 1 | 2009 | 36 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2009 | 94 | 0.020 |
Why?
|
| Pregnancy | 1 | 2012 | 961 | 0.020 |
Why?
|
| Regeneration | 1 | 2010 | 178 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2009 | 188 | 0.020 |
Why?
|
| Stem Cells | 1 | 2010 | 321 | 0.020 |
Why?
|
| Tissue Scaffolds | 1 | 2010 | 431 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2009 | 861 | 0.010 |
Why?
|